Scinai Immunotherapeutics Ltd. (SCNI)

Scinai Immunotherapeutics Ltd operates from Jerusalem as a biopharmaceutical company split between two parallel tracks. One side is pure R&D — developing next-generation antibodies for inflammatory and immune-mediated diseases, working in an area where the company senses unmet clinical need and a specific technological advantage. The other is operational and cash-generative: a contract development and manufacturing organization service line that earns recurring fees serving early-stage biotech firms through the hard parts of bringing drugs toward the clinic.

The company was born BiondVax Pharmaceuticals in 2003, developed a flu vaccine approach that entered clinical testing, and over time narrowed its focus and shifted its name to Scinai in 2023. That transition signals a pivot — out of pure-play vaccine work, into a company that can fund its science with service revenue, a common evolution for undercapitalized biotech firms with real science but limited paths to blockbuster returns.

The dual-track revenue model

Scinai’s business hinges on exploiting an asymmetry: the company has specialized scientific expertise and manufacturing scale that early-stage biotech customers need, but lack capital to build themselves. The CDMO business — contract development and manufacturing — is where the cash flow comes from. The company offers analytical method development, process optimization, and GMP manufacturing of clinical-stage drug materials. This is not glamorous, not zero-risk, but it is recurring: as long as biotech firms exist and need to make drug substance, there is work. The margin structure is reasonable because the barriers to entry are real — you cannot run a credible CDMO operation without infrastructure, regulatory approval, and deep process-chemistry talent.

Running a CDMO also creates a natural entry point into the R&D business. Scinai sees what compounds its customers are advancing, what disease areas are hot, what bottlenecks appear repeatedly. That intelligence, plus the ability to manufacture its own clinical supplies efficiently, positions the company to cherry-pick targets where it thinks it can build a differentiated asset.

The pipeline and the platform

Scinai’s research focus is narrowly targeted. The company is developing IL-17 NanoAb, a VHH-based antibody platform aimed at psoriasis and other immune-mediated inflammatory conditions. VHH antibodies are camel-derived single-domain fragments — a bit of molecular architecture that can be smaller and more nimble than conventional full-length antibodies, and sometimes more stable and easier to manufacture. Whether that confers a real clinical edge over existing psoriasis treatments (and there are many) remains unproven, but the platform is tractable and has shown promise in preclinical work.

The company is also developing PC111, a human monoclonal antibody targeting conditions like pemphigus and severe epidermal necrolysis — rare, serious, and underserved by current medicines. These are orphan indications where regulatory pathways are friendlier and patient populations are small, reducing the financial bar to success.

Both programs are early-stage. Neither has reached late-phase clinical trials or generated meaningful near-term revenue. This is the long-cycle, cash-consuming side of the business, funded partly by the CDMO cash flow and partly by periodic capital raises.

Unit economics and the funding trap

Here is where Scinai’s dual model becomes fragile. The CDMO business, while steady, operates on single-digit-percentage net margins — you are buying raw materials, paying qualified staff to make drugs, dealing with regulatory compliance, and competing on reliability rather than innovation. A profitable CDMO can return 5–15% margins if well-run, but Scinai is small and cannot yet achieve the scale that lets larger competitors sustain returns. So the cash generated is meaningful for a company this size, but not enough to fund a full clinical-stage pipeline.

That forces the company to raise capital regularly. In April 2026, Scinai raised $2.61 million from a private placement of American depositary shares and warrants — a modest sum that funded CDMO expansion and customer programs but left the core R&D portfolio thinly resourced. The pattern is familiar in small biotech: the manufacturing business buys you time and credibility, but it never quite funds the science you want to do. So you stay on a treadmill of small fundraises, each one diluting existing shareholders, each one buying a year or two of runway.

The competitive position

In psoriasis, Scinai faces entrenched competitors: multiple TNF inhibitors, newer IL-23 inhibitors like risankizumab and guselkumab have already reset the standard of care. Entering with an IL-17 VHH at this stage means proving clinical superiority or a better safety profile, a high bar when the disease is already well-treated. The rare-disease indications like pemphigus are less crowded but also more niche, meaning smaller addressable markets and slower uptake even if the compound works.

On the CDMO side, Scinai competes against much larger, well-capitalized contract manufacturers (Lonza, Catalent, Albumedix, and dozens of regional players). The only advantage a small CDMO has is nimbleness and the ability to offer hands-on service and flexibility. Once you lose that advantage by growing large, you are competing on cost and scale, terrain where Scinai cannot win. So the company must stay boutique or consolidate into a larger partner.

The research angle

Anyone tracking Scinai should watch the CDMO margins quarter to quarter. A healthy, growing CDMO arm is the company’s only realistic path to self-funded research. Equally, any update on the IL-17 or PC111 programs — preclinical data, partnership announcements, or clinical enrollment — signals whether the science is moving or stalling. The SEC 10-K filings (CIK 0001611747) lay out the pipeline, the customer concentration in the CDMO business, and the cash burn rate. Watch for signs of a pivot — if the company licenses out its antibody platform or sells the CDMO arm entirely, it signals management doubts about the dual-track model’s viability. And watch the capital-raise frequency; if fundraising accelerates while CDMO revenue stalls, the business model is under stress.